A pilot study on the effect of cognitive training on BDNF serum levels in individuals with Parkinson’s disease

Frontiers in Human Neuroscience

Volumn 9, Issue MAR, 2015, Pages

  Angelucci, Francesco ^a   Peppe, Antonella ^a   Carlesimo, Giovanni A ^a,b   Serafini, Francesca ^a   Zabberoni, Silvia ^a   Barban, Francesco ^a   Shofany, Jacob ^a   Caltagirone, Carlo ^a,b   Costa, Alberto ^a  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

BDNF; Cognitive deficits; Cognitive rehabilitation; Parkinson s disease; Serum levels

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; LEVODOPA; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE;

AGED; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COGNITION ASSESSMENT; COGNITIVE REHABILITATION; CONTROLLED STUDY; DEPTH PERCEPTION; DOUBLE BLIND PROCEDURE; EPISODIC MEMORY; EXECUTIVE FUNCTION; HUMAN; LANGUAGE ABILITY; MILD COGNITIVE IMPAIRMENT; OUTCOME ASSESSMENT; PARKINSON DISEASE; PILOT STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; WORKING MEMORY; ZOO MAP TEST;

EID: 84933673308     PISSN: None     EISSN: 16625161     Source Type: Journal    
DOI: 10.3389/fnhum.2015.00130     Document Type: Article

References (93)

1. Agid, Y., Ruberg, M., Javoy-Agid, F., Hirsch, E., Raisman-Vozari, R., Vyas, S.,et al. (1993). Are dopaminergic neurons selectively vulnerable to Parkinson's disease? Adv. Neurol. 60, 148-164.
2. Alfimova, M. V., Korovaitseva, G. I., Lezheiko, T. V., and Golimbet, V. E. (2012). Effect of BDNF Val66Met polymorphism on normal variability of executive functions. Bull. Exp. Biol. Med. 152, 606-609. doi: 10.1007/s10517-012-1587-x
3. Angelucci, F., De Bartolo, P., Gelfo, F., Foti, F., Cutuli, D., Bossù, P.,et al. (2009). Increased concentrations of nerve growth factor and brain-derived neurotrophic factor in the rat cerebellum after exposure to environmental enrichment. Cerebellum 8, 499-506. doi: 10.1007/s12311-009-0129-1
4. Bath, K. G., and Lee, F. S. (2006). Variant BDNF (Val66Met) impact on brain structure and function. Cogn. Affect. Behav. Neurosci. 6, 79-85. doi: 10.3758/CABN.6.1.79
5. Baquet, Z. C., Gorski, J. A., and Jones, K. R. (2004). Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J. Neurosci. 24, 4250-4258. doi: 10.1523/JNEUROSCI.3920-03.2004
6. Baydyuk, M., Nguyen, M. T., and Xu, B. (2011). Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration. Exp. Neurol. 228, 118-125. doi: 10.1016/j.expneurol.2010.12.018
7. Beaulieu, J. M., and Gainetdinov, R. R. (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182-217. doi: 10.1124/pr.110.002642
8. Beck, A. T., Ward, C. H., Mendelson, M., Mock, M., and Erbaugh, J. (1961). An inventory for measuring depression.Arch. Gen. Psychiatry 4, 53-63. doi: 10.1001/archpsyc.1961.01710120031004
9. Belleville, S., Clement, F., Mellah, S., Gilbert, B., Fontaine, F., and Gauthier, S. (2011). Training-related brain plasticity in subjects at risk of developing Alzheimer's disease. Brain 134, 1623-1634. doi: 10.1093/brain/awr037
10. Brusa, L., Bassi, A., Stefani, A., Pierantozzi, M., Peppe, A., Caramia, M. D.,et al. (2003). Pramipexole in comparison to l-dopa: a neuropsychological study. J. Neural. Transm. 110, 373-380. doi: 10.1007/s00702-002-0811-7
11. Calleo, J., Burrows, C., Levin, H., Marsh, L., Lai, E., and York, M. K. (2012). Cognitive rehabilitation for executive dysfunction in Parkinson's disease: application and current directions. Parkinsons Dis. 2012, 6. doi: 10.1155/2012/907513
12. Camps, M., Kelly, P. H., and Palacios, J. M. (1990). Autoradiographic localization of dopamine D1 and D2 receptors in the brain of several mammalian species. J. Neural. Transm. Gen. Sect. 80, 105-127. doi: 10.1007/BF01257077
13. Capasso, R., and Miceli, G. (2001). Esame Neuropsicologico dell'Afasia. Milano: Springer Verlag.
14. Carlesimo, G. A., Buccione, I., Fadda, L., Graceffa, A., Mauri, M., Lorusso, S.,et al. (2002). Standardizzazione di due test di memoria per uso clinico: breve racconto e figura di Rey. Nuova Rivista di Neurologia 12, 1-13.
15. Carlesimo, G. A., Caltagirone, C., and Gainotti, G. (1996). The mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The group for the standardization of the mental deterioration battery. Eur. Neurol. 36, 378-384. doi: 10.1159/000117297
16. Cohen, J. D., Braver, T. S., and Brown, J. W. (2002). Computational perspectives on dopamine function in prefrontal cortex. Curr. Opin. Neurobiol. 12, 223-229. doi: 10.1016/S0959-4388(02)00314-8
17. Cools, R. (2006). Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci. Biobehav. Rev. 30, 1-23. doi: 10.1016/j.neubiorev.2005.03.024
18. Cools, R., and D'Esposito, M. (2011). Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol. Psychiatry 69, e113-e125. doi: 10.1016/j.biopsych.2011.03.028
19. Costa, A., Monaco, M., Zabberoni, S., Peppe, A., Perri, R., Fadda, L.,et al. (2014a). Free and cued recall memory in Parkinson's disease associated with amnestic mild cognitive impairment. PLoS ONE 9:e86233. doi: 10.1371/journal.pone.0086233
20. Costa, A., Peppe, A., Mazzù, I., Longarzo, M., Caltagirone, C., and Carlesimo, G. A. (2014b). Dopamine treatment and cognitive functioning in individuals with Parkinson's disease: the cognitive flexibility hypothesis seems to work. Behav. Neurol. 2014, 260896. doi: 10.1155/2014/260896
21. Costa, A., Peppe, A., Dell'Agnello, G., Caltagirone, C., and Carlesimo, G. A. (2009). Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.Neuropsychologia 47, 1374-1381. doi: 10.1016/j.neuropsychologia.2009.01.039
22. D'Amore, D. E., Tracy, B. A., and Parikh, V. (2013). Exogenous BDNF facilitates strategy set-shifting by modulating glutamate dynamics in the dorsal striatum. Neuropharmacology 75, 312-323. doi: 10.1016/j.neuropharm.2013.07.033
23. Dao, A. T., Zagaar, M. A., Levine, A. T., Salim, S., Eriksen, J. L., and Alkadhi, K. A. (2013). Treadmill exercise prevents learning and memory impairment in Alzheimer's disease-like pathology. Curr. Alzh. Res. 10, 507-515. doi: 10.2174/1567205011310050006
24. Dirnberger, G., and Jahanshahi, M. J. (2013). Executive dysfunction in Parkinson's disease: a review. J. Neuropsychol. 7, 193-224. doi: 10.1111/jnp.12028
25. Domellöf, M. E., Elgh, E., and Forsgren, L. (2011). The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson's disease. Mov. Disord. 26, 2183-2189. doi: 10.1002/mds.23814
26. Dubois, B., Burn, D., Goetz, C., Aarsland, D., Brown, R. G., Broe, G. A.,et al. (2007). Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov. Disord. 22, 2314-2324. doi: 10.1002/mds.21844
27. El-Tamawy, M. S., Abd-Allah, F., Ahmed, S. M., Darwish, M. H., and Khalifa, H. A. (2014). Aerobic exercises enhance cognitive functions and brain derived neurotrophic factor in ischemic stroke patients.NeuroRehabilitation 34, 209-213. doi: 10.3233/NRE-131020
28. Erickson, K. I., Kim, J. S., Suever, B. L., Voss, M. W., Francis, B. M., and Kramer, A. F. (2008). Genetic contributions to age-related decline in executive function: a 10-year longitudinal study of COMT and BDNF polymorphisms.Front. Hum. Neurosci. 2:11. doi: 10.3389/neuro.09.011.2008
29. Frank, M. (2005). Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and non-medicated parkinsonism, J. Cogn. Neurosci. 17, 51-72. doi: 10.1162/0898929052880093
30. Frazzitta, G., Maestri, R., Ghilardi, M. F., Riboldazzi, G., Perini, M., Bertotti, G.,et al. (2014). Intensive rehabilitation increases BDNF serum levels in parkinsonian patients: a randomized study. Neurorehabil. Neural. Repair 28, 163-168. doi: 10.1177/1545968313508474
31. Frim, D. M., Uhler, T. A., Galpern, W. R., Beal, M. F., Breakefield, X. O., and Isacson, O. (1994). Implanted fibroblasts genetically engineered to produce brainderived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc. Natl. Acad. Sci. U.S.A. 91, 5104-5108. doi: 10.1073/pnas.91.11.5104
32. Gajewski, P. D., Hengstler, J. G., Golka, K., Falkenstein, M., and Beste, C. (2011). The Met-allele of the BDNF Val66Met polymorphism enhances task switching in elderly. Neurobiol. Aging 32, 2327.e7-2327.e19. doi: 10.1016/j.neurobiolaging.2011.06.010
33. Galloway, E. M., Woo, N. H., and Lu, B. (2008). Persistent neural activity in the prefrontal cortex: a mechanism by which BDNF regulates working memory? Prog. Brain Res. 169, 251-266. doi: 10.1016/S0079-6123(07)00015-5
34. Galpern, W. R., Frim, D. M., Tatter, S. B., Altar, C. A., Beal, M. F., and Isacson, O. (1996). Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. Cell. Transplant. 5, 225-232. doi: 10.1016/0963-6897(95)02030-6
35. Giovagnoli, A. R., Del Pesce, M., Mascheroni, S., Simoncelli, M., Laiacona, M., and Capitani, E. (1996). Trail making test: normative values from 287 normal adults controls. Ital. J. Neurol. Sci. 17, 305-309. doi: 10.1007/BF01997792
36. Gómez-Palacio-Schjetnan, A., and Escobar, M. L. (2013). Neurotrophins and synaptic plasticity. Curr. Top. Behav. Neurosci. 15, 117-136. doi: 10.1007/7854-2012-231
37. Gorski, J. A., Balogh, S. A., Wehner, J. M., and Jones, K. R. (2003). Learning deficits in forebrain-restricted brain-derived neurotrophic factor mutant mice. Neuroscience 121, 341-354. doi: 10.1016/S0306-4522(03)00426-3
38. Gothham, A. M., Brown, R. G., and Marsden, C. D. (1988). Frontal cognitive function in patients with Parkinson's disease "on" and "off" levodopa. Brain 111, 299-321. doi: 10.1093/brain/111.2.299
39. Green J., McDonald W. M., Vitek J. L., Evatt M., Freeman A., Haber M.,et al. (2002). Cognitive impairments in advanced PD without dementia. Neurology 59, 1320-1324. doi: 10.1212/01.WNL.0000031426.21683.E2
40. Gyárfás, T., Knuuttila, J., Lindholm, P., Rantamäki, T., and Castrén, E. (2010). Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo. Cell. Mol. Neurobiol. 30, 361-368. doi: 10.1007/s10571-009-9458-3
41. He, Y. Y., Zhang, X. Y., Yung, W. H., Zhu, J. N., and Wang, J. J. (2013). Role of BDNF in central motor structures and motor diseases. Mol. Neurobiol. 48, 783-93. doi: 10.1007/s12035-013-8466-y
42. Heldt, S. A., Stanek, L., Chhatwal, J. P., and Ressler, K. J. (2007). Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol. Psychiatry 12, 656-670. doi: 10.1038/sj.mp.4001957
43. Hindle, J. V., Petrelli, A., Clare, L., and Kalbe, E. (2013). Nonpharmacological enhancement of cognitive function in Parkinson's disease: a systematic review. Mov. Disord. 28, 1034-1049. doi: 10.1002/mds.25377
44. Howells, D. W., Porritt, M. J., Wong, J. Y., Batchelor, P. E., Kalnins, R., Hughes, A. J.,et al. (2000). Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp. Neurol. 166, 127-135. doi: 10.1006/exnr.2000.7483
45. Hughes, A. J., Daniel, S. E., Kilford, L., and Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181-184. doi: 10.1136/jnnp.55.3.181
46. Jahanshahi, M., Jones, C. R., Zijlmans, J., Katzenschlager, R., Lee, L., Quinn, N.,et al. (2010). Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease. Brain 133, 727-745. doi: 10.1093/brain/awq012
47. Janvin, C., Aarsland, D., Larsen, J. P., and Hugdahl, K. (2003). Neuropsycological profile of patients with Parkinson's disease without dementia. Dement. Geriatr. Cogn. Disord. 15, 126-131. doi: 10.1159/000068483
48. Kliegel, M., Altgassen, M., Hering, A., and Rose, N. S. (2011). A process-model based approach to prospective memory impairment in Parkinson's disease. Neuropsychologia 49, 2166-2177. doi: 10.1016/j.neuropsychologia.2011
49. Koponen, E., Võikar, V., Riekki, R., Saarelainen, T., Rauramaa, T., Rauvala, H.,et al. (2004). Transgenic mice overexpressing the full-length neurotrophin receptor trkB exhibit increased activation of the trkB-PLCgamma pathway, reduced anxiety, and facilitated learning. Mol. Cell. Neurosci. 26, 166-181. doi: 10.1016/j.mcn.2004.01.006
50. Koven, N. S., and Carr, L. H. (2013). The role of the brain derived neurotrophic factor C270T polymorphism in executive functioning. J. Appl. Med. Sci. 2, 25-41.
51. Lawton, M. P., and Brody, E. M. (1969). Assessment of older people; self-maintaining and instrumental activity of daily living. Gerontologist 9, 179-186. doi: 10.1093/geront/9.3_Part_1.179
52. Leentjens, A. F., Dujardin, K., Marsh, L., Martinez-Martin, P., Richard, I. H., Starkstein, S. E.,et al. (2008). Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov. Disord. 23, 2004-2014. doi: 10.1002/mds.22229
53. Lewis, S. J. G., Cools, R., Robbins, T. W., Dove, A., Barker, R. A., and Owen, A. M. (2003). Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. Neuropsychologia 41, 645-654. doi: 10.1016/S0028-3932(02)00257-9
54. Lewis, S. J. G., Foltynie, T., Blackwell, A. D., Robbins, T. W., Owen, A. M., and Barker, R. A. (2005). Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J. Neurol. Neurosurg. Psychiatry 76, 343-348. doi: 10.1136/jnnp.2003.033530
55. Li, M., Dai, F. R., Du, X. P., Yang, Q. D., Zhang, X., and Chen, Y. (2012). Infusion of BDNF into the nucleus accumbens of aged rats improves cognition and structural synaptic plasticity through PI3K-ILK-Akt signaling.Behav. Brain Res. 231, 146-153. doi: 10.1016/j.bbr.2012.03.010
56. Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C.,et al. (2012). Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement disorder society task force guidelines.Mov. Disord. 27, 349-356. doi: 10.1002/mds.24893
57. Lu, W., Zhang, C., Yi, Z., Li, Z., Wu, Z., and Fang, Y. (2012). Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naïve patients with schizophrenia. J. Mol. Neurosci. 47, 505-510. doi: 10.1007/s12031-012-9750-4
58. MacDonald, P. A., and Monchi, O. (2011). Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson's disease: implications for cognitive function. Parkinsons Dis. 2011, 572743. doi: 10.4061/2011/572743
59. Macias, M., Nowicka, D., Czupryn, A., Sulejczak, D., Skup, M., Skangiel-Kramska, J.,et al. (2009). Exercise-induced motor improvement after complete spinal cord transection and its relation to expression of brain-derived neurotrophic factor and presynaptic markers. BMC Neurosci. 10:144. doi: 10.1186/1471-2202-10-144
60. Mang, C. S., Campbell, K. L., Ross, C. J., and Boyd, L. A. (2013). Promoting neuroplasticity for motor rehabilitation after stroke: considering the effects of aerobic exercise and genetic variation on brain-derived neurotrophic factor.Phys. Ther. 93, 1707-1716. doi: 10.2522/ptj.20130053
61. Marin, R. S., Biedrzycki, R. C., and Firinciogullari, S. (1991). Reliability and validity of the apathy evaluation scale.Psychiatr. Res. 38, 143-162. doi: 10.1016/0165-1781(91)90040-V
62. Miyake, A., and Friedman, N. P. (2012). The nature and organization of individual differences in executive functions: four general conclusions. Curr. Dir. Psychol. Sci. 21, 8-14. doi: 10.1177/0963721411429458
63. Miyake, A., Friedman, N. P., Emerson, M. J., Witzki, A. H., Howerter, A., and Wager, T. D. (2000). The unity and diversity of executive functions and their contributions to complex Frontal Lobe tasks: a latent variable analysis.Cogn. Psychol. 41, 49-100. doi: 10.1006/cogp.1999.0734
64. Mohlman, J., Chazin, D., and Georgescu, B. (2011). Feasibility and acceptance of a nonpharmacological cognitive remediation intervention for patients with Parkinson disease. J. Geriatr. Psychiatry Neurol. 24, 91-97. doi: 10.1177/0891988711402350
65. Monaco, M., Costa, A., Caltagirone, C., and Carlesimo, G. A. (2013). Forward and backward span for verbal and visuo-spatial data: standardization and normative data from an Italian adult population. Neurol. Sci. 34, 749-754. doi: 10.1007/s10072-012-1130-x
66. Monteggia, L. M., Barrot, M., Powell, C. M., Berton, O., Galanis, V., Gemelli, T.,et al. (2004). Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl. Acad. Sci. U.S.A. 101, 10827-10832. doi: 10.1073/pnas.0402141101
67. Moustafa, A. A., Herzallah, M. M., and Gluck, M. A. (2013). Dissociating the cognitive effects of levodopa versus dopamine agonists in a neurocomputational model of learning in Parkinson's disease. Neurodegener. Dis. 11, 102-111. doi: 10.1159/000341999
68. Muslimovic, D., Post, B., Speelman, J. D., and Schmand, B. (2005). Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65, 1239-1245. doi: 10.1212/01.wnl.0000180516.69442.95
69. Nocentini, U., Di Vincenzo, S., Panella, M., Pasqualetti, P., and Caltagirone, C. (2002). La valutazione delle funzioni esecutive nella pratica neuropsicologica; dal modified card sorting test al modified card sorting test-roma version.Dati di standardizzazione. Nuova Rivista di Neurologia 12, 13-24.
70. Nombela, C., Bustillo, P. J., Castell, P. F., Sanchez, L., Medina, V., and Herrero, M. T. (2011). Cognitive rehabilitation in Parkinson's disease: evidence from neuroimaging. Front. Neurol. 2:82. doi: 10.3389/fneur.2011.00082
71. Oral, E., Canpolat, S., Yildirim, S., Gulec, M., Aliyev, E., and Aydin, N. (2012). Cognitive functions and serum levels of brain-derived neurotrophic factor in patients with major depressive disorder. Brain Res. Bull. 88, 454-459. doi: 10.1016/j.brainresbull.2012.03.005
72. Pang, T. Y., Stam, N. C., Nithianantharajah, J., Howard, M. L., and Hannan, A. J. (2006). Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice. Neuroscience 141, 569-584. doi: 10.1016/j.neuroscience.2006.04.013
73. Pereira, D. S., de Queiroz, B. Z., Miranda, A. S., Rocha, N. P., Felício, D. C., Mateo,E. C.,et al. (2013). Effects of physical exercise on plasma levels of brain-derived neurotrophic factor and depressive symptoms in elderly women-a randomized clinical trial. Arch. Phys. Med. Rehabil. 94, 1443-1450. doi: 10.1016/j.apmr.2013.03.029
74. Petrelli, A., Kaesberg, S., Barbe, M. T., Timmermann, L., Fink, G. R., Kessler, J.,et al. (2014). Effects of cognitive training in Parkinson's disease: a randomized controlled trial. Parkinsonism Relat. Disord. 20, 1196-1202. doi: 10.1016/j.parkreldis.2014.08.023
75. Pezawas, L., Verchinski, B. A., Mattay, V. S., Callicott, J. H., Kolachana, B. S., Straub, R. E.,et al. (2004). The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J. Neurosci.24, 10099-10102. doi: 10.1523/JNEUROSCI.2680-04.2004
76. Ramírez-Rodríguez, G., Ocaña-Fernández, M. A., Vega-Rivera, N. M., Torres-Pérez, O. M., Gómez-Sánchez, A., Estrada-Camarena, E.,et al. (2014). Environmental enrichment induces neuroplastic changes in middle age female BalbC mice and increases the hippocampal levels of BDNF, p-Akt and p-MAPK1/2. Neuroscience 260, 158-170. doi: 10.1016/j.neuroscience.2013.12.026
77. Real, C. C., Ferreira, A. F., Chaves-Kirsten, G. P., Torrão, A. S., Pires, R. S., and Britto, L. R. (2013). BDNF receptor blockade hinders the beneficial effects of exercise in a rat model of Parkinson's disease. Neuroscience 237, 118-129. doi: 10.1016/j.neuroscience.2013.05.055
78. Sakata, K., Martinowich, K., Woo, N. H., Schloesser, R. J., Jimenez, D.V., Ji, Y.,et al. (2013). Role of activity-dependent BDNF expression in hippocampal-prefrontal cortical regulation of behavioral perseverance. Proc. Natl. Acad. Sci. U.S.A. 110, 15103-15108. doi: 10.1073/pnas.1222872110
79. Sammer, G., Reuter, I., Hullmann, K., Kaps, M., and Vaitl, D. J. (2006). Training of executive functions in Parkinson's disease. Neurol. Sci. 48, 115-119. doi: 10.1016/j.jns.2006.05.028
80. Savitz, J., Solms, M., and Ramesar, R. (2006). The molecular genetics of cognition: dopamine, COMT and BDNF.Genes Brain Behav. 5, 311-328. doi: 10.1111/j.1601-183X.2005.00163.x
81. Scalzo, P., Kümmer, A., Bretas, T. L., Cardoso, F., and Teixeira, A. L. (2010). Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. J. Neurol. 257, 540-545. doi: 10.1007/s00415-009-5357-2
82. Schmolesky, M. T., Webb, D. L., and Hansen, R. A. (2013). The effects of aerobic exercise intensity and duration on levels of brain-derived neurotrophic factor in healthy men. J. Sports Sci. Med. 12, 502-511.
83. Shults, C. W., Kimber, T., and Altar, C. A. (1995). BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine. Neuroreport 6, 1109-1112. doi: 10.1097/00001756-199505300-00009
84. Tuon, T., Valvassori, S. S., Lopes-Borges, J., Luciano, T., Trom, C. B., Silva, L. A.,et al. (2012). Physical training exerts neuroprotective effects in the regulation of neurochemical factors in an animal model of Parkinson's disease.Neuroscience 227, 305-312. doi: 10.1016/j.neuroscience.2012.09.063
85. Tükel, R., Gürvit, H., Ozata, B., Oztürk, N., Ertekin, B.A., Ertekin, E.,et al. (2012). Brain-derived neurotrophic factor gene Val66Met polymorphism and cognitive function in obsessive-compulsive disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B, 850-858. doi: 10.1002/ajmg.b.32092
86. Vaughan, S., Wallis, M., Polit, D., Steele, M., Shum, D., and Morris, N. (2014). The effects of multimodal exercise on cognitive and physical functioning and brain-derived neurotrophic factor in older women: a randomised controlled trial. Age Ageing 43, 623-629. doi: 10.1093/ageing/afu010
87. Vingerhoets, F. J. G., Schulzer, M., Caine, D. B., and Snow,B. J. (1997). Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann. Neurol. 41, 58-64. doi: 10.1002/ana.410410111
88. Vinogradov, S., Fisher, M., Holland, C., Shelly, W., Wolkowitz, O., and Mellon S. H. (2009). Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol. Psychiatr. 66, 549-553. doi: 10.1016/j.biopsych.2009.02.017
89. Visser, M., Verbaan, D., van Rooden, S., Marinus, J., van Hilten, J., and Stiggelbout, A. (2009). A longitudinal evaluation of health-related quality of life of patients with Parkinson's disease. Value Health 12, 392-396. doi: 10.1111/j.1524-4733.2008.00430.x
90. Wilson, B. A., Evans, J. J., Emslie, H., Alderman, N., and Burgess, P. (1998). The development of an ecologically valid test for assessing patients with a dysexecutive syndrome. Neuropsychol. Rehab. 8, 213-228. doi: 10.1080/713755570
91. Woo, N. H., and Lu, B. (2006). Regulation of cortical interneurons by neurotrophins: from development to cognitive disorders. Neuroscientist 12, 43-56. doi: 10.1177/1073858405284360
92. Yeterian, E. H., and Pandya, D. N. (1991). Prefrontostriatal connections in relation to cortical architectonic organization in rhesus monkeys. J. Compr. Neurol. 312, 43-67. doi: 10.1002/cne.903120105
93. Ziebell, M., Khalid, U., Klein, A. B., Aznar, S., Thomsen, G., Jensen, P.,et al. (2012). Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration. Neurobiol. Aging 33, 428.e1-428.e5. doi: 10.1016/j.neurobiolaging.2010.11.010